Aquatic Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Aquatic Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.19M	Sell	19,754 -9,917	-33%	-$897K	0.08%	343
2026 Q1	$2.58M	Buy	+29,671	New	+$2.89M	0.07%	325
2025 Q4	–	Sell	-42,490	Closed	-$4.29M	–	1722
2025 Q3	$4.29M	Buy	42,490 +38,537	+975%	+$3.58M	0.08%	301
2025 Q2	$250K	Sell	3,953 -37,523	-90%	-$2.3M	0.01%	980
2025 Q1	$2.2M	Buy	41,476 +32,253	+350%	+$1.79M	0.06%	393
2024 Q4	$516K	Buy	+9,223	New	+$509K	0.01%	708
2024 Q2	–	Sell	-8,600	Closed	-$373K	–	1548
2024 Q1	$373K	Buy	+8,600	New	+$376K	0.01%	615
2023 Q4	–	Sell	-3,100	Closed	-$71K	–	1589
2023 Q3	$71K	Buy	+3,100	New	+$69.4K	﹤0.01%	899
2022 Q3	–	Sell	-2,300	Closed	-$10K	–	1497
2022 Q2	$10K	Buy	2,300 +2,000	+667%	+$10.9K	﹤0.01%	971
2022 Q1	$3K	Sell	300 -3,700	-93%	-$32.5K	﹤0.01%	926
2021 Q4	$40K	Buy	+4,000	New	+$44.9K	0.08%	374

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aquatic Capital Management's RYTM Position: Q2 2026 in Review

Aquatic Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 33% in Q2 2026, selling an estimated $897K and leaving 19,754 shares worth $2.19M. The position accounts for 0.08% of the portfolio, ranked #343.

Aquatic Capital Management first reported a position in RYTM in Q4 2021 and has held it in 11 quarters since. The position peaked at $4.29M in Q3 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Aquatic Capital Management held 19,754 shares of Rhythm Pharmaceuticals worth $2.19M as of Q2 2026.
Aquatic Capital Management sold 9,917 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $897K.
Rhythm Pharmaceuticals made up 0.08% of Aquatic Capital Management's portfolio in Q2 2026, its #343 holding.
Aquatic Capital Management first reported a position in Rhythm Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Aquatic Capital Management's Rhythm Pharmaceuticals position peaked at $4.29M in Q3 2025.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.